Sonablate Corp., a global leader in non-invasive focused ultrasound technologies, today announced that the Sonablate HIFU device is now compatible with PSMA PET.
Sonablate HIFU, in partnership with MIM Software Inc., currently allows for the import and fusion of multi-parametric MRI images from some of our fusion partners. The additional compatibility with PSMA PET will further increase precision when targeting prostate tissue.
PSMA PET is becoming an important diagnostic tool for urologists, for men who have been recently diagnosed with prostate cancer as well as men who were previously treated but have experienced a recurrence of the cancer, also known as a salvage patient. PSMA PET can identify diseased tissue that is often missed by current imaging techniques. When used in conjunction with MRI, physicians are able to incorporate the PSMA information during HIFU planning and treatment delivery.
“Sonablate HIFU now being compatible with PSMA PET is a game changer for focal therapy. Having this additional layer of information incorporated into treatment planning will provide physicians an increased level of confidence and create the most precise and customized treatment plan possible.” Says Prof. Mark Emberton of University College London.
"The ability to visualize PSMA positive regions on the Sonablate device during treatment planning and delivery represents a step change in precision medicine.” Says Dr. Arvin George of Johns Hopkins University. “I am able to optimize the treatment delivery zone with much greater confidence and ensure the best possible outcome for the patient.”
"The utilization of imaging to tailor management throughout the prostate cancer care pathway is rapidly expanding. We aim to provide physicians streamlined access to the critical information in those images at all steps in the care pathway, which is currently a major gap in urology.
In cooperation with Sonablate, we are thrilled to enable physicians to use the crucial information in PSMA PET images during HIFU planning and treatment." Says Jon Piper, Chief Scientific Officer at MIM Software Inc.
This additional compatibility is available now to current Sonablate HIFU users via a system upgrade.
For more information on Sonablate HIFU, visit www.sonablate.com.
About Sonablate Corp.
Sonablate Corp. is a world leader in non-invasive focused ultrasound technologies. Sonablate Corp. is committed to developing focused ultrasound related technologies that support precise and innovative procedures for the treatment of a range of medical conditions. Sonablate Corp., with its subsidiary Focus Surgery, Inc., designs and manufactures medical devices, including the Sonablate®, which has 510(K) clearance in the U.S and NMPA clearance in China; and Sonablate® 500, which has CE Marking and has obtained regulatory authorization in more than 50 countries outside the U.S. Caution: Federal (USA) law restricts this device to sale by or on the order of a physician. For additional information, visit www.sonablate.com.
About MIM Software Inc.
MIM Software Inc. provides practical imaging solutions in radiation oncology, radiology, nuclear medicine, urology, neuroimaging, and cardiac imaging. MIM® offers solutions for computer workstations as well as mobile and cloud-based platforms. MIM products are sold globally to imaging centers, hospitals, specialty clinics, research organizations, and pharmaceutical companies.
Sonablate® HIFU is approved in more than 50 countries worldwide and was the first focused ultrasound device to be FDA-cleared in the U.S. for the ablation of prostate tissue. This innovative solution for prostate diseases has allowed Sonablate® HIFU to become the industry leader in focal therapy. Caution: Federal (USA) law restricts this device to sale by or on the order of a physician.
Sonablate is a registered trademark of Sonablate Corp. © 2024 Sonablate Corp. All rights reserved.
